Obesity-related Gene UCP2Expression In Barrett’s Esophagus Mucosa And Clinical Significance

Objectives1. Investigate the expression of UCP2in reflux esophagitis, Barrett esophagus andesophageal adenocarcinoma.2. To assess the relationship between UCP2and BMI、WC in the Barrett’sesophagus.Material and Methods1. Collection and recording the clinical data, including age, gender, process andsymptoms, the symptoms include: acid reflux, heart burn, upper abdominaldiscomfort or pain, swallowing difficulties, extraesophageal symptom (such ascough, throat discomfort including pharyngitis, hysteria ball),and record thepatient’s height, weight and hip.2. Each patient were taken four specimens were divided into two, one into theNeutral formalin, another stored in liquid nitrogen.3. From January2010to June2011,145subjects were enrolled(30in control group,60in reflux esophagitis,45in Barrett esophagus and10in esophagealadenocarcinoma).Subproups were divided according to BMI and WC.4. Analyze the levels of MDA and SOD with thiobarbituric acid cololimitric method and xanthine oxidase method. The expression levels of TGF-β and UCP2protein in the esophageal mucosa tissue of normal control group and patients withreflux esophagitis, Barrett esophagus and esophageal adenocarcinoma weredetected by Immunohistochemistry (IHC).Results1. The levels of MDA increased progressing with the development of refluxesophagitis, into Barrett esophagus and esophageal adenocarcinoma（P<0.05),andSOD activity decreased,but there is no significance between reflux esophagitisand Barrett esophagus,and Barrett esophagus and esophageal adenocarcinoma(P>0.05).2. The levels of TGF-β increased progressing with the development of refluxesophagitis, into Barrett esophagus and esophageal adenocarcinoma,but therewas no statistically significan(P>0.05).There was no UCP2protein expression innormal squamous esophagus and increased progressing with the development ofreflux esophagitis, into Barrett esophagus and esophageal adenocarcinoma,andthere was statistically significant（P<0.05).3. The expression level of UCP2was decreased along with the increase of BMI;InRE, BE and case groups, the UCP2was significantly decreased along with theincrease of WC (P<0.05). Correlation analysis showed that the expression level ofUCP2was negatively related with WC (r=-0.889, P=0.00) and BMI (r=-0.102,P=0.237), suggesting WC has more significant correlation with the expressionlevel of UCP2.4. Relationship between obesity and BE the symptoms of GERD, including reflux ofgastric acid, upper abdominal discomfort or pain, nausea, were increased alongwith the increase of BMI, however, there was no significant difference between BMI≥24and BMI <24groups (P>0.05). The symptom of heartburn wassignificant different between these two groups (P <0.05). The symptoms of refluxof gastric acid, heartburn and upper abdominal discomfort or pain weresignificantly increased in patients of WC≥80/85(female/male) group, comparedwith those in patients of WC<80/85(female/male) group. After dividing theGERD to RE and BE groups, the symptoms of reflux of gastric acid, heartburn,upper abdominal discomfort or pain and nausea were increased along with theincrease of BMI and WC. However, WC affected the symptoms more thanBMI.ConclusionThe UCP2expression decreased in obesity Barrett’s esophagus, obesityespecially abdominal obesity increasing the risk of Barrett’s esophagus disease, andto increase in acid reflux, heartburn and other symptoms of Barrett’s esophagus. Butwhether it is the expression of UCP2reduce the lead to obesity, which led to Barrett’sesophagus, there are to be further verified.